IP Library › Granted Patent US 11,497,717
Granted Patent B2
US 11,497,717 · App. 16/955,092 · Granted Nov 15, 2022

Nanoparticles for use for treating a neuronal disorder

Inventors: Marie-Edith Meyre (Saint Mande, FR); Laurent Levy (Paris, FR); Agnès Pottier (Paris, FR)
Assignee: NANOBIOTIX S.A.
A61K9/5115A61K9/5146A61K33/24A61P25/16A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,497,717
App. No.
16/955,092
Granted
Nov 15, 2022
Kind
B2
Abstract

The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ε ijk equal to or above 200, and an insulator material with a dielectric constant ε ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.

Claims (9)

1. A method for preventing or treating a neurological disease selected from Parkinson's disease, Alzheimer's disease, epilepsy, obsessive compulsive disorder, autism spectrum disorder, depression disorder, dystonia, Tourette's syndrome, schizophrenia, stroke, aphasia, dementia, tinnitus, Huntington's disease, essential tremor, bipolar disorder, anxiety disorder, addiction disorder, and consciousness vegetative state, or at least one symptom thereof in a subject, wherein the method comprises a step of administering nanoparticle or nanoparticle aggregate, or a composition comprising nanoparticles and/or nanoparticle aggregates and a pharmaceutically acceptable support, to a subject, the material of the nanoparticle or nanoparticle aggregate being selected from the group consisting of a conductor material that is a metal having a standard reduction potential E° above 0.2 selected from Tl, Po, Ag, Pd, Ir, Pt, Au, and a mixture thereof, or an organic material having contiguous sp2 hybridized carbon centers in its structure, a semiconductor material with a band gap Eg below 3.0 eV selected from a mixed composition of elements from groups III and V of the Mendeleev's periodic table, a mixed composition of elements from groups II and VI of the Mendeleev's periodic table, and an element from group IV-A of the Mendeleev's periodic table, and an insulator material with a dielectric constant ε ijk equal to or above 200, or an insulator material with a dielectric constant ε ijk equal to or below 100 selected from Al 2 O 3 , LaAlO 3 , La 2 O 3 , SiO 2 , SnO 2 , Ta 2 O 5 , ReO 2 , ZrO 2 , HfO 2 and carbon diamond, the relative dielectric constant ε ijk being measured between 20° C. and 30° C. and between 10 2 Hz up to the infrared frequency, wherein i) the median largest size of the core of the nanoparticle or nanoparticles' aggregate of the population is of at least 30 nm when the material is a conductor material, a semiconductor material or an insulator material with a dielectric constant ε ijk equal to or above 200, and wherein ii) the core of the nanoparticle or nanoparticle aggregate is coated with a biocompatible coating providing a neutral or a negative surface charge when measured in a solution of water having a concentration of electrolytes between 0.001 and 0.2 M, the concentration of the nanoparticle or nanoparticle aggregate material is between 0.01 and 10 g/L and a pH between 6 and 8, wherein iii) the method does not include any step of exposing the nanoparticles or nanoparticle aggregates to an electric field nor to any other external activation source, wherein iv) the nanoparticles or nanoparticle aggregates remain in the subject, and wherein v), the nanoparticles or aggregates of nanoparticles is not used as carriers of therapeutic compound(s) or drug(s).

2. The method according to claim 1 , wherein the conductor material is selected from Ir, Pd, Pt, Au, and any mixture thereof, and an organic material having contiguous sp2 hybridized carbon centers in its structure, said organic material being selected from polyaniline, polypyrrole, polyacetylene, polythiophene, polycarbazole, polypyrene and any mixture thereof.

3. The method according to claim 1 , wherein the nanoparticle's or nanoparticles aggregate's material is an element from group IV-A of the Mendeleev's periodic table and is doped with a charge carrier selected from Al, B, Ga, In and P.

4. The method according to claim 1 , wherein the insulator material with a band gap Eg equal to or above 3.0 eV and the relative dielectric constant ε ijk is-equal to or above 200 is a dielectric material which is a mixed-metal oxide selected from BaTiO 3 , KTaNbO 3 , KTaO 3 , SrTiO 3 and BaSrTiO 3 .

5. The method according to claim 1 , wherein the insulator material with a band gap Eg equal to or above 3.0 eV and a relative dielectric constant ε ijk equal to or below 100 is selected from ReO 2 , ZrO 2 and HfO 2 .

6. The method according to claim 1 , wherein the neurological disease is Parkinson's disease or Alzheimer's disease.

7. The method according to claim 1 , wherein the composition comprises at least two distinct nanoparticles and/or nanoparticle aggregates.

8. A composition or kit comprising at least two distinct nanoparticles and/or nanoparticle aggregates, the nanoparticles' or nanoparticles aggregates' material being selected from the group consisting of a conductor material that is a metal having a standard reduction potential E° above 0.2 selected from Tl, Po, Ag, Pd, Ir, Pt, Au, and a mixture thereof, or an organic material having contiguous sp2 hybridized carbon centers in its structure, a semiconductor material with a band gap Eg below 3.0 eV selected from a mixed composition of elements from groups III and V of the Mendeleev's periodic table, a mixed composition of elements from groups II and VI of the Mendeleev's periodic table, and an element from group IV-A of the Mendeleev's periodic table, and an insulator material with a dielectric constant ε ijk equal to or above 200, and an insulator material with a dielectric constant ε ijk equal to or below 100 selected from Al 2 O 3 , LaAlO 3 , La 2 O 3 , SiO 2 , SnO 2 , Ta 2 O 5 , ReO 2 , ZrO 2 , HfO 2 and carbon diamond, the relative dielectric constant ε ijk being measured between 20° C. and 30° C. and between 10 2 Hz up to the infrared frequency, wherein i) the median largest size of the core of the nanoparticle or nanoparticle aggregate of the population is of at least 30 nm when the material is a conductor material, a semiconductor material or an insulator material with a dielectric constant ε ijk equal to or above 200, and wherein ii) the core of the nanoparticle or nanoparticles aggregate is coated with a biocompatible coating providing a neutral or a negative surface charge when measured in a solution of water having a concentration of electrolytes between 0.001 and 0.2 M, the concentration of the nanoparticle or nanoparticle aggregate material is between 0.01 and 10 g/L and a pH between 6 and 8.

9. The method according to claim 1 , wherein the element from group IV-A of the Mendeleev's periodic table is silicon (Si) or Germanium (Ge).

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 053362 FRAME 0506. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Recorded Jan 21, 2022
From: MEYRE, MARIE-EDITH; LEVY, LAURENT; POTTIER, AGNÈS
To: NANOBIOTIX S.A.
Reel/Frame 058802/0012 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2020
From: MEYRE, MARIE-EDITH; LEVY, LAURENT; POTTIER, AGNÈS
To: NANOBIOTIX
Reel/Frame 053362/0506 →
Priority Claims (1)
EP 17306826 · Dec 19, 2017 · regional
Continuity (1)
Related Publication 20210015756A1 · Jan 21, 2021
Cited By (1)
US 12,653,890